Ukkat J, Lorenz K, Hinze R, Thomusch O, Dralle H
Department of General Surgery, Martin-Luther-University Halle-Wittenberg, Ernst-Grube-Strasse 40, D-06097 Halle/Saale, Germany.
World J Surg. 2001 Jun;25(6):713-7. doi: 10.1007/s00268-001-0020-9.
Genetic testing for RET germline mutations affords rapid identification of germline carriers, offering the prospect of cure before C-cell hyperplasia (CCH) has progressed to medullary thyroid carcinoma (MTC). Although nonindex RET mutation carriers have a better prognosis than do the index patients, it remains to be ascertained whether age represents a risk factor for MTC when screening patients. The current institutional study (October 1994 through June 1999) was set up to compare asymptomatic nonindex patients who were grouped by age: < 20 years and > or = 20 years. Inclusion criteria were confirmed RET mutations in the germline, with no MTC being more advanced than pT1pN1M0. Adult patients (> or = 20 years) had MTC significantly more often (84% vs. 43%), significantly larger tumors (5 mm vs. 3 mm), and significantly higher basal calcitonin levels preoperatively (78.0 vs. 9.7 pg/ml) than their pediatric/adolescent counterparts (< 20 years). There was a close correlation between pT1 MTC and an elevated basal serum calcitonin level (r = 0.67; Spearman's rho). All three patients with lymph node metastases from MTC had elevated basal calcitonin levels. The two groups did not differ in terms of multifocality of MTC (pT1b), lymph node involvement (pN1) or bilateral lymph node metastasis (pN1b), or preoperative stimulated and postoperative basal and stimulated serum calcitonin. Prophylactic thyroidectomy should not be postponed beyond the age of 20, and it should be performed before basal serum calcitonin has turned positive. Pathologic conversion of stimulated serum calcitonin obviously marks the time in carriers of RET germline mutations when surgery should be scheduled at the latest to be prophylactic.
对RET基因种系突变进行基因检测能够快速识别种系突变携带者,为在C细胞增生(CCH)进展为甲状腺髓样癌(MTC)之前实现治愈提供了可能。尽管非索引RET突变携带者的预后比索引患者更好,但在对患者进行筛查时,年龄是否为MTC的危险因素仍有待确定。当前的机构研究(1994年10月至1999年6月)旨在比较按年龄分组的无症状非索引患者:<20岁和≥20岁。纳入标准为确认种系中存在RET突变,且MTC不超过pT1pN1M0期。成年患者(≥20岁)发生MTC的频率显著更高(84%对43%),肿瘤显著更大(5毫米对3毫米),术前基础降钙素水平显著更高(78.0对9.7皮克/毫升),高于其儿科/青少年对应者(<20岁)。pT1期MTC与基础血清降钙素水平升高密切相关(r = 0.67;Spearman秩相关系数)。所有3例发生MTC淋巴结转移的患者基础降钙素水平均升高。两组在MTC的多灶性(pT1b)、淋巴结受累(pN1)或双侧淋巴结转移(pN1b)方面,以及术前刺激后和术后基础及刺激血清降钙素方面无差异。预防性甲状腺切除术不应推迟至20岁以后,应在基础血清降钙素转为阳性之前进行。刺激血清降钙素的病理转化显然标志着RET基因种系突变携带者最晚应安排手术进行预防的时间。